GU Cancers 2022 | TIVO-3: tivozanib hydrochloride vs sorafenib for refractory advanced RCC
Michael Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington DC, DC, discusses results of the TIVO-3 (NCT02627963) trial comparing the VEGFR tyrosine kinase inhibitor (TKI), tivozanib hydrochloride, to sorafenib in patients with refractory advanced renal cell carcinoma (RCC). The initial results demonstrated a superior progression-free survival (PFS) for tivozanib verses sorafenib, with a 4-5 year follow-up showing approximately five times as many patients progression-free with tivozanib than with sorafenib. Although there was no initial overall-survival (OS) benefit, as time continued an increased OS with tivozanib compared to sorafenib was observed, concluding tivozanib as a superior TKI than sorafenib in the 3rd- and 4th-line setting for patients with advanced RCC. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.
